Analysis of Diphenylcyclopropenone (DPCP) in Normals

Completed · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The drug diphenylcyclopropenone, or DPCP, modifies the immune system and has been shown to be effective in treating certain kinds of cancer. This study hopes to improve our understanding of how this drug helps create an effective immune response.

Key facts

Study ID

NCT01452594

Run by

Rockefeller University

People needed

30

Starts

2011-10-01

Expected to finish

2013-09-01

Last updated by the study team

2013-09-05

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or non-pregnant female between 18 and 60 years of age
• Able to give verbal and written informed consent
• For women of childbearing potential (WOCBP) or in men whose partners may become pregnant, willingness to use an acceptable method of contraception to prevent pregnancy for the duration of the study (while receiving study medication and for one month following the last dose of study medication). Acceptable forms of contraception are listed in the protocol.
• Must have a negative urine pregnancy test (for WOCBP)

You may not qualify if…

• Subjects taking any of the following systemic or topical therapies within 4 weeks of enrollment: corticosteroids, immunosuppressants, and/or any other medications that may affect the outcome of the study
• Known sensitivity to bandage or adhesive tape.
• Subjects who have active localized or systemic medical conditions that, in the opinion of the investigator, would preclude or make unsafe their participation in the study
• Subjects with any underlying concomitant diagnosis that may influence immune reactions (e.g. eczema, psoriasis, lupus)
• Subjects who are nursing mothers, pregnant, or planning to become pregnant at anytime during the course of the study or within 30 days of study completion
• Subjects who are unable to comply with study procedures, communicate effectively, cooperate with the investigator, or are unable to understand the study
• Subjects who have been treated with another investigational device or drug within 30 days of enrollment
• HIV positive as determined by self-reported history and/or a HIV POCT at screening
• History, physical, social or lab findings suggestive of any medical or psychological condition that would, in the opinion of the PI, make the candidate ineligible for the study

Where it is running

• The Rockefeller University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.